Sign up for the free White House Watch newsletter Your guide to what the 2024 US election means for Washington and the world Donald Trump is set to unveil billions of dollars of private investment in a massive new artificial…
CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. (“Cosmos Health” or “Company”) (NASDAQ:)A diversified, integrated, integrated healthcare group engaged in innovative R & D, owner of a pharmaceutical and nutraceutical brand, manufacturer and marketer of…
Kona Ice CEO Tony Lamb and Lions Chicken Fingers CEO Garrett Reid explain why President Trump is good for their business. From Wall Street to Main Street, business leaders are beginning to express hope that President Donald Trump will bring…
The YieldMax AAPL Option Income Strategy ETF publishes a dividend of $0.1667 Source link
Oracle (ORCL) stock jumped as much as 6% after a report said the company is poised to be part of a $500 billion investment in AI infrastructure that will be announced by President Trump on Tuesday. CBS News reported Tuesday…
Reports suggest OpenAI is about to make a big announcement about AI agents. But his last big announcement already looks a little dubious. Read More Source link
Sign up for the free White House Watch newsletter Your guide to what the 2024 US election means for Washington and the world What effect will the second coming of Donald Trump have on the world? The world is unpredictable.…
Tuesday's market saw significant movement among stocks, with some companies experiencing significant gains while others faced declines. Mega-cap stocks like Oracle Company (NYSE: ) and Apple Computer Inc (NASDAQ:) have been making headlines with their intraday stock movements, capturing the…
Travel expert Mark Murphy shares his top tips for booking travel as travelers ramp up for the holiday season. JetBlue Airways is now accepting Venmo as a payment option For its flights, according to the carrier, it first identifies an…
hapapapa Dyne Therapeutics (NASDAQ:DYN) announced Tuesday that the US Food and Drug Administration (FDA) has granted fast-track designation for DYNE-101, an experimental therapy for a rare muscle disorder called myotonic dystrophy type 1 (DM1). DYNE-101, a drug with orphan drug…
